Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 7448 |
| PDBID: | 6GWP |
| Chains: | B_A |
| Organism: | Homo sapiens, Vicugna pacos |
| Method: | XRD |
| Resolution (Å): | 2.28 |
| Reference: | 10.1111/jth.14716 |
| Antibody | |
| Antibody: | VHH-2g-42 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Plasminogen activator inhibitor-1 (PAI-1) |
| Antigen mutation: | Yes |
| Durg Target: | P05121; P05121; |
Sequence information
Antibody
Chain: B
Mutation: NULL
| >6GWP_B|Chain B|VHH-2g-42|Vicugna pacos (30538) QVQLVESGGGLVQPGGRLRLSCAASGFTFRTYAMQWYRQSPGTERELVAAISNIGGVTDYGDSVKGRFTISRDNAKTTVYLEMNSLKPEDTATYYCSAVRLPQRYWGRGTQVTVSS |
Antigen
Chain: A
Mutation: N150H/K154T/Q301P/Q319L/M354I
| >6GWP_A|Chain A|Plasminogen Activator Inhibitor-1|Homo sapiens (9606) VHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISHLLGTGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRPFQADFTSLSDQEPLHVALALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIIDRPFLFVVRHNPTGTVLFMGQVMEP |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| B: ARG30 THR31 ALA33 GLN35 ALA50 ILE51 SER52 ASN53 ILE54 GLY55 VAL57 THR58 ASP59 VAL99 ARG100 LEU101 ARG104 A: THR211 GLU212 PHE213 THR214 THR215 PRO216 ASP217 GLY218 HIS219 TYR220 GLU242 ILE253 LEU258 HIS261 TRP262 ASN265 THR267 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
